• LAST PRICE
    2.8900
  • TODAY'S CHANGE (%)
    Trending Down-0.1700 (-5.5556%)
  • Bid / Lots
    2.8800/ 33
  • Ask / Lots
    3.0200/ 3
  • Open / Previous Close
    3.0800 / 3.0600
  • Day Range
    Low 2.8400
    High 3.0800
  • 52 Week Range
    Low 2.8400
    High 8.4000
  • Volume
    310,415
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Line Graph See accessible table below
News Volume Accessibility Table
DateIndex Fund Price vs. News Density
11/4$3.81
11/5$3.73
11/8$3.68
11/9$3.62
11/10$3.51
11/11$3.47
11/12$3.46
11/15$3.42
11/16$3.46
11/17$3.38
11/18$3.22
11/19$3.33
11/22$3.35
11/23$3.29
11/24$3.38
11/26$3.41
11/29$3.30
11/30$3.37
12/1$3.21
12/2$3.06
12/3$2.89

9:15AM ET on Friday Nov 12, 2021 by GlobeNewswire
Companies Mentioned: CAPR

Capricor Therapeutics (NASDAQ: CAPR) ("Capricor" or "the Company"), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, today announced that Dr. Linda Marban, CEO of Capricor, has accepted an invitation to serve as the keynote speaker at the TriLink Biotechnologies Annual mRNA Day Conference, taking place virtually on November 16, 2021.

5:45PM ET on Tuesday Nov 09, 2021 by Thomson Reuters
Companies Mentioned: CAPR

Nov 9 (Reuters) - Capricor Therapeutics Inc:

* CAPRICOR THERAPEUTICS REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

* Q3 LOS...

4:05PM ET on Tuesday Nov 09, 2021 by GlobeNewswire
Companies Mentioned: CAPR

CAP-1002 - Capricor's Cell Therapy Program for Duchenne Muscular Dystrophy

-Phase 3 Pivotal Study Cleared to Proceed-

-Presented Positive Phase 2 HOPE-2 Data at Late-Breaking Oral Presentation at the World Muscle Society Annual Meeting-

Peers Headlines

Dec 1, 2021

8:00AM ET on Wednesday Dec 01, 2021 by Accesswire
Companies Mentioned: EDSA

Nov 22, 2021

Nov 8, 2021

9:54AM ET on Monday Nov 08, 2021 by MT Newswires
Companies Mentioned: TARA

Nov 4, 2021

8:02AM ET on Thursday Nov 04, 2021 by Accesswire
Companies Mentioned: EDSA